Permanent Intracranial Stenting for Acute Ischemic Stroke Related to a Refractory Large Vessel Occlusion
Condition(s) studied
Investigational drug(s) / intervention(s)
Intracranial stenting: In order to promote the efficacy of the stent to reopen the target vessel, there are two requirments prior stenting: First, balloon angioplasty can be performed at operators' discretion based on angiographic findings. Second, a dual antiplatelet therapy protocol is considered essential to maintain stent patency, and therefore should be introduced before stent implantation whenever possible. Permanent Intracranial can then be performed according to the standard technique: An autoexpandable intracranial stent (Neuroform Atlas 4x24mm) is deployed though a dedicated microcatheter over the target refractory occlusion The only stent system allowed is the Neuroform Atlas 4x24mm (Stryker Neurovascular) The anti-thrombotic drugs used, their route of administration, the choice of navigation equipment are left to the discretion of the team in charge of the patient. A standardized anti-thrombotic protocol will be proposed as an indication.
Optimal medical care, without additional endovascular procedures: The control group represents the standard therapeutic strategy for refractory vascular occlusions, which consists of stopping the procedure without performing any additional mechanical thrombectomy attempts. In this group, the procedure will be stopped after randomization and a control seriography will be performed to confirm the persistent nature of the intracranial occlusion. The patient will benefit from the best medical care available, which may include any medical treatment including a dual anti-platelet therapy if the therapeutic team deems it necessary (Standard medical care may also include (non-exhaustive list): * Nursing * Nursing care * Symptomatic treatments: analgesics for example * Systematic clinical monitoring and control imaging if necessary * Rehabilitation if necessary)
Study summary
Clot extraction failure during mechanical thrombectomy is a major concern in the management of acute ischemic stroke related to large vessel occlusions. Indeed, it can occur in up to 10 to 30% of cases and, therefore, is associated with a very poor prognosis. These refractory occlusions frequently occur when an underlying intracranial atherosclerotic disease is present. Thus, one of the most promising rescue technique consists of placing a permanent intracranial stent, under dual antiplatelet therapy over the target refractory occlusion. This strategy is well studied in coronary occlusions where the atheroscotic mechanism is highly prevalent. However, as the ischemiated brain is at much higher risk of hemorrhagic complications, such strategy entails a greater risk. This raises the question of whether such risk is worth the reward of obtaining reperfusion. The investigators designed this randomized study in order to evaluate whether a strategy combining rescue pemanent intracranial stenting with the best medical treatment is superior to the best medical treatment alone in acute refractory large vessel occlusions.
Eligibility
Primary outcome measure(s)
- Rate of independent patients — 3 months
Rate of independent patients at 3 months, defined as a modified Rankin Scale (mRS) 0-2, evaluated by a trained health professional, blinded to the randomization arm. Min=0 ; Max=6 (lower is better)
Trial sites (13)
| Facility | City | Region | Status |
|---|---|---|---|
| CHU Amiens | Amiens | France | |
| CHU Bordeaux (Pellegrin Hospital) | Bordeaux | France | |
| Henri-Mondor Hospital (APHP) | Créteil | France | |
| Henri-Mondor Hospital (APHP) | Créteil | France | |
| Bicêtre Hospital (AP-HP) | Le Kremlin-Bicêtre | France | |
| Bicêtre Hospital (APHP) | Le Kremlin-Bicêtre | France | |
| CHU Lille (Roger Salengro Hospital) | Lille | France | |
| CHU Montpellier - Gui de Chauliac | Montpellier | France | |
| CHRU de Nancy | Nancy | France | |
| Lariboisière Hospital (APHP) | Paris | France | |
| APHP • Assistance Publique des Hôpitaux de Paris, Pitié-Salpêtrière hospital | Paris | France | |
| CHU Poitiers | Poitiers | France | |
| Foch Hospital | Suresnes | France |
More Assistance Publique - Hôpitaux de Paris trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06071091 on ClinicalTrials.gov ↗ ← All trials in France